Life Expectancy News and Research

RSS

Life expectancy is the expected (in the statistical sense) number of years of life remaining at a given age. It is denoted by e''x'', which means the average number of subsequent years of life for someone now aged ''x'', according to a particular mortality experience.

Genzyme, Alnylam partner to develop and commercialize RNAi therapeutics against ATTR

Alnylam Pharmaceuticals, Inc. and Genzyme, a Sanofi company, announced today that they have formed an exclusive alliance to develop and commercialize RNAi therapeutics targeting transthyretin (TTR) for the treatment of transthyretin-mediated amyloidosis (ATTR) in Japan and other Asia-Pacific countries.

23 Oct 2012

Sickle cell disease treatments: An interview with Dr Niihara, CEO of Emmaus Medical

Sickle cell disease is a devastating hereditary condition that affects millions of people, particularly those in West and Central Africa as well as people of African descent in the United States, Europe and South America.

23 Oct 2012

Study evaluates international data on kidney transplantation

Kidney transplants performed in Europe are considerably more successful in the long run than those performed in the United States.

15 Oct 2012

One rule for one and one for another with diabetes

A joint consensus statement from the European Association for the Study of Diabetes and the American Diabetes Association encourages a shift in attitude over glycemic management in Type 2 diabetes.

12 Oct 2012

Clear link between neurotensin and CVD, type 2 diabetes and breast cancer

"It was surprising to find such a clear link to the risk of type 2 diabetes and cardiovascular disease as well as to breast cancer. Obesity is a common risk factor for all three conditions, but the connection with neurotensin is not explained by obesity or other known risk factors", says Professor Olle Melander from the Department of Clinical Sciences at Lund University, who is also a consultant at Sk-ne University Hospital.

11 Oct 2012

Addiction and mental health burden higher than all cancers in Ontario

Mental illnesses and addictions take more of a toll on the health of Ontarians than cancer or infectious diseases, according to a new report by the Institute for Clinical Evaluative Sciences and Public Health Ontario - yet this burden could be reduced with treatment, say scientists from Canada's Centre for Addiction and Mental Health.

11 Oct 2012

Viewpoints: Key issues for Romney, Obama to address in the debate; Peter G. Peterson's mission to cut entitlements

With the U.S. population aging, Social Security and Medicare are projected to account for a growing share of the federal budget and the economy. To accommodate that change, should federal spending (and revenue) amount to a larger share of the economy than it has historically? If not, how does Washington make ends meet?

4 Oct 2012

FDA grants Fast Track designation to XBiotech’s Xilonix for treatment of cachexia

XBiotech, a privately held biotechnology company, announced today that the company has been granted Fast Track designation for its anti-cachexia drug Xilonix.

4 Oct 2012

Roche announces availability of new HIV-1 viral load test in the U.S.

Roche announced today the U.S. availability of a new HIV-1 viral load test based on the company's proprietary dual-target approach. The COBAS TaqMan HIV-1 Test v2.0 for use with the High Pure System enables labs to combine an FDA-approved process for manual specimen preparation with an automated real-time PCR analyzer for amplification and detection.

From Roche Sequencing and Life Science 4 Oct 2012

InterMune receives Health Canada approval for Esbriet to treat idiopathic pulmonary fibrosis

InterMune, Inc. today announced that Health Canada has approved Esbriet (pirfenidone) for the treatment of mild to moderate idiopathic pulmonary fibrosis (IPF) in adult patients.

3 Oct 2012

One rule for one and one for another with diabetes

A joint consensus statement from the European Association for the Study of Diabetes and the American Diabetes Association encourages a shift in attitude over glycemic management in Type 2 diabetes.

2 Oct 2012

Self-harming and premature death: an interview with Prof Keith Hawton, University of Oxford Centre for Suicide Research

“Self-harm” is the term used in the UK, much of Europe and elsewhere, to describe intentional self-poisoning or self-injury. Thus it includes overdoses, attempted hanging, self-cutting etc.

2 Oct 2012

September issue of JNCCN publishes two prostate cancer articles

Julio M. Pow-Sang, M.D., chair of Moffitt Cancer Center's Department of Genitourinary Oncology, and colleagues have published two prostate cancer articles in the September issue of JNCCN - The Journal of the National Comprehensive Cancer Network. The articles review and clarify recent updates made to the National Comprehensive Cancer Network's (NCCN) guidelines for the screening and treatment of prostate cancer.

29 Sep 2012

Increase in rates of short telomeres predicts longevity in mammals

A team of researchers from the Spanish National Cancer Research Centre (CNIO), headed by CNIO Director Mar-a Blasco, has demonstrated in a pioneering study on mammals that longevity is defined at a molecular level by the length of telomeres. The work-which is published today in the online edition of the journal Cell Reports-opens the door to further study of these cellular components in order to calculate the rate at which cells age and thus be able to determine life expectancy for a particular organism.

28 Sep 2012

New report: Population aging will have broad economic consequences for the U.S.

The aging of the U.S. population will have broad economic consequences for the country, particularly for federal programs that support the elderly, and its long-term effects on all generations will be mediated by how -- and how quickly -- the nation responds, says a new congressionally mandated report from the National Research Council.

26 Sep 2012

Risk for cardiovascular disease begins early in life

A new multi-national survey reveals the extent of misconceptions about when is the right time to start taking action to prevent cardiovascular disease (CVD). In a four-country survey sample of 4,000 adults, 49 per cent answered age 30 years or older when asked at what age they believe people should start to take action about their heart health to prevent conditions such as heart disease and stroke.

24 Sep 2012